What is Inhibrx Biosciences, Inc.'s non-cash lease expense?

Inhibrx Biosciences, Inc. (INBX) reported non-cash lease expense of $483K in Q1 2026.

How has Inhibrx Biosciences, Inc.'s non-cash lease expense changed year-over-year?

Inhibrx Biosciences, Inc.'s non-cash lease expense increased by 11.3% year-over-year, from $434K to $483K.

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:NoncashOperatingLeaseExpense.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Inhibrx Biosciences, Inc.'s non-cash lease expense?: Inhibrx Biosciences, Inc. (INBX) reported non-cash lease expense of $483K in Q1 2026.
How has Inhibrx Biosciences, Inc.'s non-cash lease expense changed year-over-year?: Inhibrx Biosciences, Inc.'s non-cash lease expense increased by 11.3% year-over-year, from $434K to $483K.